Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
[1] Allergic reactions range from local injection site reactions (erythema, swelling, pruritus) to serious systemic symptoms including generalized urticaria, angioedema affecting the face or throat, respiratory difficulty, and anaphylaxis with cardiovascular collapse
If you're struggling with weight loss and think either Wegovy or Tirzepatide might be right for you, we'd love to help
They can provide information on any copayments, deductibles, or prior authorization requirements
That said, unless your doctor says otherwise, there is usually no harm in taking a daily supplement